key: cord-0939507-4zyg3gmx authors: Montagutelli, Xavier; van der Werf, Sylvie; Rey, Felix A; Simon‐Loriere, Etienne title: SARS‐CoV‐2 Omicron emergence urges for reinforced One‐Health surveillance date: 2022-01-27 journal: EMBO Mol Med DOI: 10.15252/emmm.202115558 sha: a2cb1cac0b4cfd17164ae616c125c597b1845f8c doc_id: 939507 cord_uid: 4zyg3gmx SARS‐CoV‐2 Omicron harbors substitutions in the receptor binding domain of the spike which strongly suggest its capacity to infect rodents. Wild animal reservoirs could favor the emergence of new variants with risks of spillback to humans and should be closely monitored.[Image: see text] 5th Jan 2022 1st Editorial Decision 5th Jan 2022 Dear Prof. Rey, Thank you for the submission of your manuscript to EMBO Molecular Medicine. I am pleased to inform you that we will be able to accept your manuscript pending the following final amendments: 1) Please address all the referee's comments. -Add conflict of interest statement. 4) Please provide 2 sentences that summarise the main message of the article. 5) Funding: Please make sure that information about all sources of funding are complete in both our submission system and in the manuscript. 6) As part of the EMBO Publications transparent editorial process initiative (see our Editorial at http://embomolmed.embopress.org/content/2/9/329), EMBO Molecular Medicine will publish online a Review Process File (RPF) to accompany accepted manuscripts. This file will be published in conjunction with your paper and will include the anonymous referee reports, your point-by-point response and all pertinent correspondence relating to the manuscript. Let us know whether you agree with the publication of the RPF and as here, if you want to remove or not any figures from it prior to publication. Please note that the Authors checklist will be published at the end of the RPF. In this correspondence, the authors discussed the zoonotic capacity of SARS-CoV-2 virus. By analyzing the mutations in the RBD of spike protein of field and mouse-adapted SARS-CoV-2 viruses, the authors believe that Omicron variant could have acquired the capability to circulate in animal reservoirs, especially in rodents. Overall, this study is timely and critical to our understanding of characterization of the Omicron variant. Suggestion: Minor revise Comment: 1. It will not be surprising if the Omicron variant could infect rodents, and it is possible that rodents may become a reservoir of the Omicron variant. Since many other animals, especially those in closer contact with humans, have been reported to be susceptible to SARS-CoV-2 (PMID: 32269068; PMID: 34676095), a discussion on the risks of the infection and circulation of Omicron variants in other animals will add much value to this correspondence. 2. In Fig 1, a mouse-adapted strain HRB26M with mutation Q498H in RBD of spike protein (PMID: 32749592) should be discussed. Paris, January 6 th , 2022 Comments: 1. It will not be surprising if the Omicron variant could infect rodents, and it is possible that rodents may become a reservoir of the Omicron variant. Since many other animals, especially those in closer contact with humans, have been reported to be susceptible to SARS-CoV-2 (PMID: 32269068; PMID: 34676095), a discussion on the risks of the infection and circulation of Omicron variants in other animals will add much value to this correspondence. We have added a sentence to the text to extend our comment to other animal species that could constitute a potential reservoir risk. This is indeed already well exemplified with the very recent publication of the detection of SARS-CoV-2 in white-tailed deer populations in North America. Please note that the sentence has increased the main text length to 413 characters. No additional reference was added due to the limitation imposed by the journal. However, reference 1 provides a complete and updated list of animal species reported infected with SARS-CoV-2. Fig 1, a mouse-adapted strain HRB26M with mutation Q498H in RBD of spike protein (PMID: 32749592) should be discussed. We have included the mouse adapted strain suggested by the reviewer, however we added a note in the figure legend as this virus also carries a 5-amino-acid deletion in the RBD (residues 675-679), next to the polybasic cleavage site, which, as noted by the authors could have played a role in the adaptation to mice. We are pleased to inform you that your manuscript is accepted for publication and is now being sent to our publisher to be included in the next available issue of EMBO Molecular Medicine. the assay(s) and method(s) used to carry out the reported observations and measurements an explicit mention of the biological and chemical entity(ies) that are being measured. an explicit mention of the biological and chemical entity(ies) that are altered/varied/perturbed in a controlled manner. a statement of how many times the experiment shown was independently replicated in the laboratory. Any descriptions too long for the figure legend should be included in the methods section and/or with the source data. In the pink boxes below, please ensure that the answers to the following questions are reported in the manuscript itself. Every question should be answered. If the question is not relevant to your research, please write NA (non applicable). We encourage you to include a specific subsection in the methods section for statistics, reagents, animal models and human subjects. definitions of statistical methods and measures: a description of the sample collection allowing the reader to understand whether the samples represent technical or biological replicates (including how many animals, litters, cultures, etc.). For experiments involving live vertebrates, include a statement of compliance with ethical regulations and identify the committee(s) approving the experiments. NA 10. We recommend consulting the ARRIVE guidelines (see link list at top right) For publication of patient photos, include a statement confirming that consent to publish was obtained. 14. Report any restrictions on the availability (and/or on the use) of human data or samples Report the clinical trial registration number (at ClinicalTrials.gov or equivalent) For phase II and III randomized controlled trials, please refer to the CONSORT flow diagram (see link list at top right) and submit the CONSORT checklist (see link list at top right) with your submission. See author guidelines, under 'Reporting Guidelines Provide a "Data Availability" section at the end of the Materials & Methods, listing the accession codes for data generated in this study and deposited in a public database (e.g. RNA-Seq data: Gene Expression Omnibus GSE39462, Proteomics data: PRIDE PXD000208 etc Data deposition in a public repository is mandatory for: a. Protein, DNA and RNA sequences Deposition is strongly recommended for any datasets that are central and integral to the study; please consider the journal's data policy. If no structured public repository exists for a given data type, we encourage the provision of datasets in the manuscript as a Supplementary Document (see author guidelines under 'Expanded View' or in unstructured repositories such as Dryad (see link list at top right) or Figshare Access to human clinical and genomic datasets should be provided with as few restrictions as possible while respecting ethical obligations to the patients and relevant medical and legal issues. If practically possible and compatible with the individual consent agreement used in the study, such data should be deposited in one of the major public accesscontrolled repositories such as dbGAP (see link list at top right) or EGA Computational models that are central and integral to a study should be shared without restrictions and provided in a machine-readable form. The relevant accession numbers or links should be provided. When possible, standardized format (SBML, CellML) should be used instead of scripts (e.g. MATLAB) Could your study fall under dual use research restrictions? Please check biosecurity documents (see link list at top right) and list of select agents and toxins (APHIS/CDC) (see link list at top right). According to our biosecurity guidelines